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The insulin-like growth factor 1 receptor (IGF-1R) has surfaced as a significant target in multiple solid cancers due
to its fundamental roles in pro-survival and anti-apoptotic signaling. However, development of resistance to IGF-1R
blockade represents a significant hindrance and limits treatment efficacy in the clinic. In this study, we identified
acquired resistance to IGF-1R blockade with R1507, an antibody against IGF-1R, and with BMS-754807, a small
molecular inhibitor of IGF-1R/insulin receptor (IR). We showed that treatment with an IGF-IR antibody, R1507, or an
IR/IGF-IR kinase inhibitor, BMS-754807, was associated with increased activation of YES/SRC family tyrosine
kinase (SFK) in rhabdomyosarcoma (RMS). Combining anti–IGF-1R agents with SFK inhibitors resulted in blockade
of IGF-1R inhibition–induced activation of YES/SFK and displayed advantageous antitumor activity in vitro and
in vivo. Our data provide evidence that IGF-1R blockade results in activation of the YES/SRC family kinase bypass
resistance pathway in vitro and in vivo. This may be of particular clinical relevance since both Yes and IGF
components are overexpressed in RMS. Increased YES/SFK activation might serve as a clinical biomarker for
predicting tumor resistance to IGF-1R inhibition. Dual inhibition of IGF-1R and SFK may have a broader and
enhanced clinical benefit for patients with RMS.
Neoplasia (2015) 17, 358–366Address all correspondence to: Xiaolin Wan, MD, PhD, or Lee J. Helman, MD,
Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Clinical Research Center, 1W-3816, 10 Center Drive,
Bethesda, MD 20892, USA.
E-mail: xiaolinw@mail.nih.gov
1This research was supported by the Intramural Research Program of the Center for
Cancer Research, National Cancer Institute, National Institutes of Health. Disclosure
of potential conflicts of interest: none.
Received 21 October 2014; Revised 2 March 2015; Accepted 9 March 2015
Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1476-5586/15
http://dx.doi.org/10.1016/j.neo.2015.03.001Introduction
Uncontrolled cell growth is central to carcinogenesis. Growth factors, as
well as growth factor–initiated pathways that regulate cell growth
control and modulate cell phenotype are undoubtedly important to the
etiology of cancer. Studies aimed at deciphering the role of insulin/
insulin-like growth factor (IGF) receptors and their cognate ligands in
cancer biology have been ongoing for more than three decades due to
their pivotal roles in regulating tumor cell growth, differentiation,
tumor angiogenesis, metastasis, apoptosis, and resistance to chemo-
therapy [1]. To date, no cancer-specific mutations of the IGF 1 receptor
(IGF-1R) or its ligands have been reported. The IGF signaling pathway
is abnormally activated, either by loss of genomic imprinting or by
abnormal stimulation by endocrine, autocrine, and paracrine mecha-
nisms, in various pediatric sarcomas [2–4]. These changes lead to
dysregulation of sarcoma growth and contribute to subsequent sarcoma
development and progression. Hence, targeting of IGF signaling,
specifically IGF-1R blockade, has emerged in recent years as a
promising therapeutic approach in pediatric sarcomas. However, recent
phase II clinical trials with several anti–IGF-1R monoclonal antibodieshave shown relatively low response rates. For example, the Roche IGF–
1R monoclonal antibody, R1507, showed modest therapeutic efficacy
in 115 patients with recurrent or refractory Ewing sarcoma family of
tumors, with an overall objective response rate of 10%. Furthermore,
even in responding patients, most responses were transient, lasting less
than 18 weeks. Thus, the majority of patients, even those with initial
responses, do not have long-term benefit from IGF-IR blockade,
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recruitment of compensatory pathways allowing for continued growth
[5]. We previously reported similar results in a rhabdomyosarcoma
(RMS) xenograft model where tumors developed resistance after
continuous treatment with IGF-1R antibody [6]. Therefore, there is
clearly a need to identify resistance mechanisms to IGF-1R blockade
and hopefully identify combination approaches that will improve on
these early observations.
SRC family tyrosine kinases (SFKs) are non-receptor tyrosine
kinases that are involved in multiple signaling pathways controlling
cell growth, survival, differentiation, and migration, in response to the
activation of cell surface receptors by growth factors, cytokines, and
adhesion proteins [7,8]. SFKs consist of at least nine highly
homologous family members: SRC, YES, FYN, LYN, LCK, HCK,
FGR, BLK, and YRK, each composed of four SRC homology
domains (SH1, SH2, SH3, and SH4) that share similar structure and
function [9,10]. Although the SFKs are activated in various types of
cancers, the exact mechanisms through which they contribute to the
progression of individual tumors remain to be defined. As SFKs play
important roles in the promotion of cell proliferation, adhesion,
invasion, and motility, SFK has become a therapeutic target for drug
development. Several SFK inhibitors, such as dasatinib, AZD0530,
and SKI-606, are entering clinical trials as anticancer therapeutics [9].
Dasatinib is a multitargeted tyrosine kinase inhibitor that has been
found to target BCR-ABL, SFKs (SRC, LCK, YES, and FYN), c-Kit,
ephrin receptor A2, and PDGF receptor (PDGFR), which is capable
of binding to these kinases, inhibiting their autophosphorylation and
downstream phosphorylation of additional targets and thus blocking
their oncogenic activities [11]. Dasatinib has been approved for the
treatment of imatinib-resistant or imatinib-intolerant forms of
chronic myeloid leukemia and Philadelphia chromosome-positive
acute lymphoblastic leukemia [12]. Previous studies have found that
SFKs are involved in signaling from many receptor tyrosine kinases
(RTKs) including PDGFR, epidermal growth factor receptor, fibroblast
growth receptor, and IGF-1R [13]. SRC interacts with multiple RTKs
through its SH2 domain and facilitates RTK-mediated signaling. We
recently demonstrated that YES is highly expressed and functional in
RMS [14]. These data led us to determine whether activation of YES
might play a role in bypass resistance to IGF-IR inhibition.
In this study, we demonstrate that IGF-1R blockade results in an
increase in Yes activation and is associated with resistance to IGF-1R
blockade in RMS cell lines. On the basis of these findings, we tested
IGF-1R blockade combined with SFK inhibition using the commer-
cially available drug, dasatinib, as well as an independent SFK inhibitor,
AZD0530. Dual blockade of IGF-1R and SFK pathways showed
superior efficacy in vitro and in vivo. These data suggest that IGF-1R
inhibition–induced activation of YES/SFKmay act as a bypass pathway.
Furthermore, these data suggest that dual IGF-1R and SFK kinase
inhibition may lead to improved therapeutic outcomes.
Materials and Methods
Cell Lines and Cell Culture
Alveolar RMS cell lines Rh30 and Rh41 and embryonal RMS cell
line RD have been previously described [15]. ARMS cell lines Rh5
and Rh28 and ERMS cell line Rh18 and TTC442 were obtained
from Dr Javed Khan (NCI, Bethesda, MD). The cells were
maintained in RPMI growth medium (Invitrogen, Carlsbad, CA)
with 10% FBS (Sigma-Aldrich, St Louis, MO), 100 U/ml penicillinand 100 μg/ml streptomycin (Invitrogen), and 2 mM L-glutamine
(Invitrogen) at 37°C in an atmosphere of 5% CO.
Compounds
AZD0530, dasatinib, and Gleevec were purchased from LC
Laboratories (Woburn, MA). R1507 antibody was obtained from
Roche Inc (Nultey, NJ), and h7C10 antibody was obtained from
Merck Inc (Kenilworth, NJ). BMS-754807 was obtained from
Bristol-Myers Squibb Inc (New York, NY).
Real-Time Polymerase Chain Reaction
Total RNA was isolated from each cell line, RD, Rh28, Rh30, and
Rh41, withQiagenRNeasyMini Kit (74104). RNA (1μg) was used for
cDNA synthesis with Roche Transcriptor First-Strand cDNA Synthesis
Kit (04379012001) using anchored oligo-dT. Normal human skeletal
muscle RNA was purchased from Zyagen (San Diego, CA).
YES1 forward primer (ACAGCAAGACAAGGTGCAAA)
and reverse primer (GTAAACCGACCATACAGTGCAG) and
glyceraldehyde-3-phosphate dehydrogenase forward primer
(AGGTCGGTGTGAACGGATTTG) and reverse primer (TGTA-
GACCATGTAGTTGAGGTCA) were used with Power SYBR Green
PCR Master Mix (Applied Biosystems, Grand Island, NY) for
quantitative polymerase chain reactions (PCRs) in a Bio-Rad C100
thermal cycler, and the result was analyzed with Bio-Rad CFX software.
Annealing temperature was 55.7°C for both YES1 andGADPHprimers.
Western Blot Analysis and Immunoprecipitation
Western blot analysis was done as published previously [16].
Antibodies to phospho-SFK (Tyr416), SRC, phospho-Akt (S473),
cleaved caspase-3 (Asp175), and cleaved poly ADP ribose polymerase
(PARP) (Asp214) were purchased from Cell Signaling Technology Inc
(Beverly, MA). Anti-phosphotyrosine antibody was purchased from
Millipore Inc. (Billerica, MA). Anti-YES used for immunoprecipitation
(IP) was fromWako (Richmond, VA). Mouse anti-SRC antibodies for
IP were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-actin
antibody was purchased from Abcam Inc. (Cambridge, MA). IP assays
were performed using the Universal Magnetic Co-IP kit from Active
Motif Inc. (Carlsbad, CA) following the manufacturer’s instruction.
Cell Proliferation and Survival Assays
Cell proliferation and survival was determined using 3-(4,5-
dimethylthiazolyl-2)-2, 5-diphenytetrazolium bromide (MTT) assay as
described previously [17]. Cell proliferation kinetics weremonitored and
recorded with the IncuCyte System (Essen BioScience, Ann Arbor, MI).
In Vivo Study
Animal studies were performed in accordance with the guidelines of
the National Institutes of Health Animal Care and Use Committee.
Four- to 6-week-old female Fox Chase severe combined immunode-
ficiency-Beige mice were purchased from Charles River Laboratories
(Wilmington, MA). Three million cells of Rh30 and RD were injected
orthotopically into the gastrocnemius muscle in the left hind leg.
Treatment with agents began when tumor was palpable, on day 14 in
Rh30 tumor–bearing mice. In RD tumor–bearing mice, treatment
began on day 11 after injection, before tumors were palpable. Dasatinib
was given by oral gavage at 100 mg/kg daily × 5 days/week. R1507 was
given IP at 6 mg/kg twice a week. Tumor volume was calculated by the
following formula: V (mm3) = (D × d2)/6 × 3.14, where D is the
longest tumor axis and d is the shortest tumor axis.
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Figure 1. (A and B) cDNA expression profile shows expression levels of IGF-1, IGF-2, IGF-1R, and SFKs in human RMS (ERMS, embryonal
RMS, ARMS, and alveolar RMS) cell lines [C], xenograft tumors of human cell lines [X], and human tumor tissue [T]. For comparison,
non-RMS tumors and normal human skeletal muscle are shown. The Affy ID refers to specific probes used in U133 plus 2.0 Arrays and are
designed to provide multiple probes for the same gene. The scale is median centered (in log2) with a saturation threshold of +2 (red;
four-fold higher) to −2 (green; four-fold lower). (C) By quantitative PCR, YES1 RNA expression in RMS cell lines was higher compared to
expression in normal human skeletal muscle (NSM). YES and GADPH SQ values were generated with Bio-RAD CFX software and
normalized to GADPH. (D) YES expression and SFK phosphorylation were analyzed by Western blot analysis in RMS cell lines.
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Statistical analyses were performed in Prism version 4.0 (GraphPad
Software) using a nonparametric t test. Statistical significance was
defined as P b .05.
Results
IGF-2, IGF-1R, and YES Kinase are Highly Expressed in RMS
Our previous studies have demonstrated that IGF-2 is over-
expressed and functions in an autocrine manner in RMS [16,18] and
that YES kinase is overexpressed in RMS. [14] We also examined
expression of other members of SFKs in addition to YES, IGF-1,
IGF-2, and IGF-1R, in cell lines, xenografts, and human tumor
samples of RMS by cDNA microarray (Oncogenomic Database,
http://home.ccr.cancer.gov/oncology/oncogenomics/). As shown in
Figure 1A, IGF-2 and IGF-1R are both highly expressed in cell lines,
xenografts, and human tumor samples of RMS. We further
confirmed that YES is highly expressed in almost all cell lines,
xenografts, and human tumor samples of RMS compared to
expression of other SFKs and non-RMS tumors. In contrast, both
SRC and LYN are minimally expressed in RMS cell lines and tumors
(Figure 1B). Data from quantitative reverse transcription–PCR
further demonstrate that YES is highly expressed in RMS cell linescompared to normal human skeletal muscle (Figure 1C). These
results suggest that YES is the predominantly expressed SFK in RMS.
In addition, Western blot analysis revealed that YES protein is
expressed, while phospho-SFK is expressed at modest levels in seven
RMS cell lines (Figure 1D).IGF-1R Inhibition Induces Activation of YES Kinase
Since IGFs and YES are both highly expressed in RMS cell lines
and tumor samples, we examined the effect of anti–IGF-1R agents on
the phosphorylation of SFK and downstream targets involved in the
IGF-1R signaling pathway. As shown in Figure 2A, Western blot
analysis identified that single-agent treatment with either of the
IGF-1R inhibitors, R1507 or BMS-754807, or both agents in
combination for 24 hours resulted in an increase in phosphorylation
of SFK (Tyr416). This appeared to be further enhanced with
combination IGF-1R inhibition in both Rh30 and RD cell lines.
Treatment of cells with dual anti–IGF-1R and SFK inhibitors
resulted in blockade of IGF-1R inhibition–induced activation of
SFK. Phosphorylation of Akt was downregulated in the face of both
single-agent IGF-1R or SFK inhibition and dual IGF-1R and SFK
blockade. Further, rapid up-regulation of SFK activation was
observed within 4 hours of IGF-1R blockade in RMS cell lines
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Figure 2. IGF-1R inhibition is associated with a compensatory increase in YES/SFK activation. (A and B) Cells were treated with
single-agent R1507, BMS-754807, or dasatinib or in combination using dasatinib with R1507/BMS-754807 at 24 (A) or 4 hours (B). Both
single-agent R1507 and BMS-754807 induced an increase of SFK phosphorylation at 24-hour treatment (A) and 4-hour treatment (B) by
Western blot analysis. (C and D) IGF-1R inhibition–induced up-regulation of SFK activation is specifically associated with YES. Protein
lysates from Rh30 and RD cells with or without R1507 treatment at indicated times were immunoprecipitated with normal IgG, SRC, and
YES antibodies overnight. These blots were probed with mouse anti-phosphotyrosine, SRC, or YES antibodies (C). (D) The
phosphotyrosine intensities from C were scanned and analyzed by ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA). (E) The
levels of cleaved caspase-3 and PARP were significantly increased with combination IGF-1R and SFK inhibition. Apoptosis was
determined by cleaved caspase-3 and PARP. Western blot analysis demonstrates a significant increase in cleaved caspase-3 and PARP at
24 hours of combination treatment compared to single-agent treatment.
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regulation of SFK activation is specifically associated with YES
activation, we performed IP assays with SRC and YES-specific
antibodies followed by immunoblot analysis with an anti-
phosphotyrosine antibody. A significant increase in YES tyrosine
phosphorylation was detected following 4 hours of R1507 treatment
in Rh30 and 24 hours of R1507 treatment in RD, compared to a
minimal increase in phosphorylation of SRC (Figure 2, C and D).
These results suggest that IGF-1R inhibition induces YES activation.
To evaluate whether dual blockade of IGF-1R and SFK can augment
cellular apoptotic response, we determined the levels of cleaved
caspase-3 and cleaved PARP, key biochemical markers of apoptosis.
Significantly increased cleaved caspase-3 and cleaved PARP were
observed after 24 hours of treatment with anti–IGF-1R agents incombination with the SFK inhibitor dasatinib, when compared to
treatment with each agent alone (Figure 2E). These results suggest
that IGF-1R inhibition–induced activation of YES kinase may act as a
bypass resistance pathway.
Effects of Dual Inhibition of IGF-1R and SFK on Cell Growth
Inhibition of RMS In Vitro
Since both IGF signaling and SFK pathways play important roles
in cell growth and survival, we tested the rationale for combined
inhibition of IGF and SFK in RMS cell lines in vitro. Inhibition of
IGF-1R and SFK with a combination of R1507 and the SFK
inhibitor AZD0530 resulted in more potent inhibition of both RD
and Rh30 cell growth than did either agent alone or other combined
treatments including R1507 plus Gleevec (Figure 3A). Since Gleevec
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Figure 3. Effects of dual inhibition of IGF-1R and SFK on RMS cell growth in vitro. (A and B) Both RD and Rh30 cells were plated onto a
96-well plate (5000 cells per well) in regular growth medium. After 16 hours of incubation, cells were treated with single agent or
combined agents as indicated in the figures for 48 hours (*P b .0001; 10 μMAZD0530 + R1507 vs R1507 or 10 μMAZD0530 alone in both
Rh30 and RD cell lines) (A) or 72 hours (*P b .0001; 10 μMAZD0530 + h7C10/R1507 vs 10 μMAZD0530 or R1507 alone in Rh30 cell line;
**P b .0005; 1 μM AZD0530 + h7C10/R1507 vs 1 μM AZD0530 or R1507 alone in Rh30 cell line; ***P b .05-.001; 1 μM AZD0530/10 μM
AZD0530+h7C10/R1507 vs 1 μMAZD0530/10 μMAZD0530 alone in RD cell line) (B). (C) Cells were treatedwith dasatinib alone at a range of
concentrations from0.01 to 10 μMor in combinationwithR1507 at a fixed concentration (100nM) for 72 hours. Cell growthwasmeasured by
MTT (*P b .0002-.0001; 10 nM-10 μMdasatinib+ R1507 vs 10 nM-10 μMdasatinib alone in both Rh30 and RD cell lines. (D) The combination
of dasatinib and BMS-754807, a small-molecule inhibitor of IGF-1R/IR, results in more potent inhibition of RMS cell growth than does either
agent alone. Cells were treated with single agent alone or combined agents for 72 hours as indicated. Images were taken 4 hours after
incubation with MTT.
362 Rationale for dual target of IGF-1R and YES/SFK Wan et al. Neoplasia Vol. 17, No. 4, 2015(also known as imatinib) is a tyrosine kinase inhibitor with activity
against Bcr-Abl, c-Kit, and PDGFR that lacks activity against SFK,
the lack of enhanced activity with the combination of Gleevec plus
IGF-IR blockade in this assay further points to the activation of YES
as a potential bypass resistance pathway induced by IGF-IR blockade.Similar results were observed with combined treatment using h7c10,
another IGF-1R antibody that has been used previously [17]
(Figure 3B). We also tested the combination of R1507 and dasatinib.
Both RD and Rh30 cells were treated with dasatinib (10 nM to 10 μM)
alone or in combination with R1507 for 72 hours. The combination of
Figure 4. Effects of dual inhibition of IGF-1R and SFK on cell growth were examined in additional RMS cell in vitro. Rh5, Rh28, and TTC442
cells were plated onto a 96-well plate and treated with single-agent R1507 (100 nM), BMS-754807 (1 μM), or dasatinib (100 nM) or in
combination using dasatinib (100 nM) with R1507 (100 nM)/BMS-754807 (1 μM). These cells were monitored and recorded with the
IncuCyte System. Arrow indicates beginning of treatment.
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effects on cell growth (Figure 3C). In addition, combined treatment of
RMS cells with BMS-754807 (1 μM), a small molecule inhibitor of the
IGF-1R/IR and dasatinib (1 μM), led to more effective inhibition of
RMS cell growth than each agent alone, as shown in Figure 3D.
We next examined the effect of dual inhibition of IGF-1R and
YES/SFK on additional ARMS cell lines Rh5 and Rh28 and ERMS
cell line TTC442. The combination of dasatinib (100 nM) and
R1507 or BMS-754807 significantly inhibited cell growth and
survival compared to single agent alone in all tested cell lines
(Figure 4). These data suggest that dual blockade of IGF-1R and
SFKs has efficacy in RMS in vitro.Effect of Combination of R1507 and Dasatinib on Growth of
RMS Xenografts In Vivo
We next sought to determine whether the effect of dual IGF-1R
and SFK inhibition observed in vitro would translate to the in vivo
setting. The in vivo antitumor efficacy of R1507 and dasatinib alone
and in combination was tested in xenograft models of RMS. We
treated RMS xenograft–bearing mice with R1507 and dasatinib alone
or in combination beginning when tumor was palpable (day 14) in
Rh30 tumor–bearing mice and 11 days after tumor injection for RD
tumor–bearing mice. As shown in Figure 5, R1507 alone significantly
inhibited xenograft growth compared to the control group after 31
days of treatment for Rh30 xenografts (Figure 5B) and 60 days of
treatment for RD xenografts (Figure 5E; P b .0001 for R1507 group
vs vehicle group in both models); dasatinib alone had less effect ontumor growth inhibition compared to R1507 alone (P = .0795 in
Rh30 model and P = .041 in RD model for R1507 group vs vehicle
group; Figure 5, B and E). In the Rh30 model, all mice in both of the
R1507 and dasatinib groups developed resistance to single-agent
treatment by 55 days of treatment (P = .117 for R1507 group and P =
.1114 for dasatinib group; Figure 5C). In the RD model, most of the
mice in both the R1507 and dasatinib groups developed resistance to
single-agent treatment by 79 days of treatment (P = .4309 for R1507
group and P = .7167 for dasatinib group; Figure 5F). Combining
R1507 and dasatinib led to more significant inhibition of tumor
growth (P b .0001 in both models), and some tumors did not become
resistant even after 55 or 79 days of treatment (Figure 5, C and F).
IGF-1R Inhibition Induces Activation of YES/SFK In Vivo
To confirm whether IGF-1R inhibition induced activation of SFK in
vivo, xenograft tumor lysates from each treatment group were subjected
to Western blot analysis. As seen in Figure 5, G andH, treatment with
R1507 increased SFK phosphorylation in both RD and Rh30
xenografts, whereas R1507 in combination with dasatinib abrogated
this increase in SFK activation. These data further demonstrate that
IGF-1R inhibition induces YES/SFK activation in vivo.
Discussion
Disruption of the IGF-1R signaling pathway has proven to be a
promising therapeutic strategy in a variety of human cancers due to its
role in cancer cell proliferation, survival, tumor angiogenesis, and
metastasis [1]. We recently completed a phase II study targeting the
IGF-1R signaling pathway in refractory Ewing’s and other sarcomas.
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Figure 5. Dual IGF-1R and SFK blockade inhibit RMS xenograft growth. (A and D) Mice were injected with 3 × 106 RD cells per mouse
into the gastrocnemius muscle of the left hind leg. Treatment with agents began when tumor was palpable (day 14) in Rh30 tumor–
bearing mice (A) and 11 days following injection of cells in RD tumor–bearing mice (B). Dasatinib was given by oral gavage at 100mg/kg
daily× 5. R1507was given IP at 6mg/kg twice aweek. Tumor growthwasmeasured twice perweek, and tumor volumewas determined
using the formula (D× d2/6 × 3.14). (B and C)Measured tumor volume of each of the individual mice bearing Rh30 xenografts shown on
day 45 (B) and day 69 (C) post-injection. (E and F)Measured tumor volume of each of the individualmice bearing RD xenografts shownon
day 71 (B) and day 90 (C) post-injection. (G and H) SFK phosphorylation was analyzed by Western blot in RD (G) and Rh30 (H) xenograft
tumor samples.
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responses were transient lasting less than 18 weeks. The majority of
patients, even those with initial responses, do not have long-term
benefit from IGF-1R blockade, indicating the presence of both an
innately resistant tumor mass as well as acquired resistance to the
anti–IGF-1R antibody R1507 [5]. Thus, it is important to identify
the mechanisms of resistance to IGF-1R blockade so that rational
therapeutic strategies can be identified to overcome resistance. The
aim of this study was to identify the mechanisms of acquired
resistance to IGF-1R inhibition. In the present study, we identified
activation of YES/SFK as a consequence of IGF-IR blockade in RMS
cell lines and xenografts. On the basis of these observations, we then
demonstrated that combined treatment with IGF-1R antibody plus
SFK kinase inhibition enhanced growth inhibitory activity both
in vitro and in vivo and led to prolonged responses in vivo.
Accumulating studies have reported that multiple mechanisms of
acquired resistance are involved with IGF-1R inhibition. heat shock
protein 90 has been reported to stabilize IGF-1R in some cancers and
to increase following IGF-1R inhibition [19]. Overexpression of IGFbinding proteins 3 and 6 might alter ligand stability and lead to
resistance to IGF-1R inhibitors [20]. PDGFR-A was found to confer
resistance to IGF-1R inhibitor in a drug-selected RMS cell line [21].
A recent report found that formation of IGF-1R and Her2
heterodimers is one of the mechanisms of rapidly developing
resistance to IGF-1R inhibitors in primary mouse RMS cells [22].
It is not surprising that multiple mechanisms of resistance may
operate depending on the cellular context as well as other variables.
Furthermore, since IGF signaling is such a central biologic process,
multiple redundant pathways should be anticipated in reaction to
IGF blockade.
SFKs are activated in various types of cancer, but the family
member(s) that contribute to the progression of individual tumors
have not yet been defined. Because currently available SFK inhibitors
are all dual SRC/Abl inhibitors and target multiple members of the
SFKs, we cannot conclude that YES is the only target of dual
inhibition experiments. We recently identified CRKL/YES as critical
interrelated pathways necessary for RMS growth and survival by a
loss-of-function screen using an inducible small hairpin RNA library
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dramatically inhibited RMS cell growth. These data suggest that YES
seems to play a more important role in the regulation of RMS cell
growth and survival.
IGF-1R/IR hybrid receptors are activated by IGF-1 and IGF-2
with similar function to IGF-1R in cancer [23,24]. IR has been
reported to contribute to resistance to IGF-1R blockade [25]. It has
therefore been suggested that IGF-1R/IR kinase inhibitors may prove
to be more effective than IGF-1R antibody therapy by blocking both
IR and IGF-1R. However, at least in our study, we found that
targeting both IR and IGF-1R with the kinase inhibitor
BMS-754807 also resulted in activation of YES. Our study therefore
suggests that both IGF-1R blockade by anti-IGF-1R antibody and
IGF-1R blockade by IGF-1R/IR small molecule inhibitors are
associated with increased activation of YES. This finding may be of
particular relevance clinically, since both YES and IGF components
are overexpressed in RMS tumors (Figure 1). Increased YES/SFK
activation might serve as a biomarker for predicting tumor
resistance to IGF-1R inhibition clinically. In addition to IGF-1R
inhibition, increased SFK activation has also been implicated in
epidermal growth factor receptor inhibitor–mediated resistance
mechanisms in different types of cancer [26,27]. Therefore,
activation of SFK may confer a broader role for RTK blockade–
mediated resistance.
The mechanism for IGF-1R inhibition–induced SFK activation is
not clear. Shin et al. reported that increased SRC activation occurring
with IGF-1R blockade in human head and neck squamous cell
carcinoma and non–small cell lung cancer cell lines is associated with
integrin β3 [28]. To determine whether integrin β3 is a potential
mediator for increased YES/SFK activation on IGF-1R blockade, we
co-treated RMS cells with anti–integrin β3 and anti-R1507
antibodies. However, anti–integrin β3 antibody did not affect
IGF-1R inhibition–induced YES/SFK activation (data not shown).
Thus, in RMS, IGF-1R blockade–induced YES/SFK activation is
independent of integrin β3 signaling. It is possible that the compensatory
activation of the YES/SFK pathway represents an important adaptive
survival response in which cancer cells become resistant to IGF-1R–
targeted therapeutics. Since IGF-1R lacks mutations and/or amplifica-
tions in cancer cells, induction of alternate compensatory pathways may
be the more expected resistance mechanism. Therefore, combined
targeting of IGF-IR and SFK may provide a new impetus for more
effective applications of this targeted therapy.
In summary, we identified a mechanism of IGF-1R blockade–
induced Yes/SFK activation responsible for acquired resistance to
IGF-1R blockade in RMS. Due to the heterogeneous nature of
tumors and alternative survival pathways developed during
treatment, it is likely that additional resistance mechanisms may
coexist or develop. It is clear even from our experiments that not all
mice were cured with dual IGF-1R/YES blockade, and additional
pathways became critical. These additional pathways remain to be
studied in the future. Nonetheless, our data clearly suggest
potential therapeutic strategies that could be employed now for
potential patient benefit.
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